SCHEMBL5845582

SCHEMBL5845582

CC1(C)CCC(C)(C)c2cc(-c3cc(-c4ccc(C(=O)OCc5ccccc5)cc4)ccc3O)ccc21

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ RARB P10826 14/20 0.69
▸ RARG P13631 13/20 0.69
▸ RARA P10276 12/20 0.69
▸ RXRA P19793 3/20 0.54
▸ LMNA P02545 1/20 0.48
▸ SLC6A2 P23975 1/20 0.45
▸ SLC6A3 Q01959 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL344714 0.87 RARB (0.71) RARBRARGRARARXRA
SCHEMBL5845460 0.84 RARG (0.57) RARBRARGRARARXRA
SCHEMBL5846741 0.84 RARB (0.65) RARBRARGRARARXRA
SCHEMBL5846275 0.82 RARG (0.60) RARBRARGRARARXRA
SCHEMBL8839024 0.82 KMT2A (0.56) RARBRARGRARARXRALMNA
SCHEMBL3677978 0.82 RARB (1.00) RARBRARGRARARXRA
SCHEMBL5845556 0.82 RARG (0.57) RARBRARGRARARXRAKMT2A
SCHEMBL5845489 0.81 RARG (0.50) RARBRARGRARARXRALMNA
SCHEMBL5847640 0.79 RARG (0.59) RARBRARGRARARXRA
SCHEMBL5845461 0.78 RARB (0.92) RARBRARGRARARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148245-B2 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-12-12 — — US disclosed
US-20040030141-A1 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT 2004-02-12 — — US disclosed
US-6649612-B1 Combating skin ageing and keratinization GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-11-18 — — US disclosed
US-6316009-B1 FOR THERAPY OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH A KERATINIZATION DISORDER, AND FOR COMBATING AGEING OF THE SKIN GALDERMA RESEARCH & DEVELOPMENT (FR) 2001-11-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040030141-A1 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them AHR, TYR, CYP1A1 RARB 26/4885RARG 39/4885RARA 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback